Literature DB >> 20425404

The role of molecular tests in acute myelogenous leukemia treatment decisions.

Gabriela Motyckova1, Richard M Stone.   

Abstract

The prognosis for patients with acute myelogenous leukemia (AML) is dependent on age, karyotype, and the genetics of the neoplastic cell. The molecular markers with prognostic impact include mutations in FLT3, NPM1, MLL, WT1, c-KIT, and expression levels of BAALC, NM1, ERG, and CXCR4. Gene expression profiles and microRNA expression patterns in AML may prove highly useful in defining the prognosis of AML. Cytogenetic and, increasingly, molecular findings are used in determining the best therapy for AML patients, especially the choice of whether to perform allogeneic stem cell transplantation.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20425404     DOI： 10.1007/s11899-010-0049-7

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  55 in total

1.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Authors:  Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Tamara Vukosavljevic; Peter Paschka; Susan P Whitman; Christian Langer; Claudia D Baldus; Chang-Gong Liu; Amy S Ruppert; Bayard L Powell; Andrew J Carroll; Michael A Caligiuri; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

Review 2.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

3.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Authors:  Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

4.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

Authors:  Roberto Cairoli; Alessandro Beghini; Giovanni Grillo; Gianpaolo Nadali; Francesca Elice; Carla Barbara Ripamonti; Patrizia Colapietro; Michele Nichelatti; Laura Pezzetti; Monia Lunghi; Antonio Cuneo; Assunta Viola; Felicetto Ferrara; Mario Lazzarino; Francesco Rodeghiero; Giovanni Pizzolo; Lidia Larizza; Enrica Morra
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

Review 5.  Ras signaling and therapies.

Authors:  Amy Young; Jesse Lyons; Abigail L Miller; Vernon T Phan; Irma Rangel Alarcón; Frank McCormick
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

6.  Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Authors:  Christian Langer; Guido Marcucci; Kelsi B Holland; Michael D Radmacher; Kati Maharry; Peter Paschka; Susan P Whitman; Krzysztof Mrózek; Claudia D Baldus; Ravi Vij; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

Authors:  Claudia D Baldus; Stephan M Tanner; Amy S Ruppert; Susan P Whitman; Kellie J Archer; Guido Marcucci; Michael A Caligiuri; Andrew J Carroll; James W Vardiman; Bayard L Powell; Steven L Allen; Joseph O Moore; Richard A Larson; Jonathan E Kolitz; Albert de la Chapelle; Clara D Bloomfield
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

8.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

Authors:  Verena Ingeborg Gaidzik; Richard Friedrich Schlenk; Simone Moschny; Annegret Becker; Lars Bullinger; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

9.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Authors:  Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-Gong Liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

10.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113
View more
  13 in total

1.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

Review 2.  Translating next generation sequencing to practice: opportunities and necessary steps.

Authors:  Sitharthan Kamalakaran; Vinay Varadan; Angel Janevski; Nilanjana Banerjee; David Tuck; W Richard McCombie; Nevenka Dimitrova; Lyndsay N Harris
Journal:  Mol Oncol       Date:  2013-05-15       Impact factor: 6.603

3.  Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.

Authors:  Philippe Armand; Haesook T Kim; Mei-Jie Zhang; Waleska S Perez; Paola S Dal Cin; Thomas R Klumpp; Edmund K Waller; Mark R Litzow; Jane L Liesveld; Hillard M Lazarus; Andrew S Artz; Vikas Gupta; Bipin N Savani; Philip L McCarthy; Jean-Yves Cahn; Harry C Schouten; Jürgen Finke; Edward D Ball; Mahmoud D Aljurf; Corey S Cutler; Jacob M Rowe; Joseph H Antin; Luis M Isola; Paolo Di Bartolomeo; Bruce M Camitta; Alan M Miller; Mitchell S Cairo; Keith Stockerl-Goldstein; Jorge Sierra; M Lynn Savoie; Joerg Halter; Patrick J Stiff; Chadi Nabhan; Ann A Jakubowski; Donald W Bunjes; Effie W Petersdorf; Steven M Devine; Richard T Maziarz; Martin Bornhauser; Victor A Lewis; David I Marks; Christopher N Bredeson; Robert J Soiffer; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-31       Impact factor: 5.742

4.  RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

Review 5.  Environmental chemicals and microRNAs.

Authors:  Lifang Hou; Dong Wang; Andrea Baccarelli
Journal:  Mutat Res       Date:  2011-05-14       Impact factor: 2.433

6.  Treatment of elderly acute myeloid leukemia patients.

Authors:  Gabriela Motyckova; Richard M Stone
Journal:  Curr Treat Options Oncol       Date:  2011-12

7.  Chromosomal aberrations in hematological malignancies: A guide to the identification of novel oncogenes.

Authors:  Babu Rao Vundinti; Kanjaksha Ghosh
Journal:  Indian J Hum Genet       Date:  2011-05

Review 8.  An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment.

Authors:  Tiziana Grafone; Michela Palmisano; Chiara Nicci; Sergio Storti
Journal:  Oncol Rev       Date:  2012-04-17

9.  Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations.

Authors:  Afia Muhammad Akram; Asma Chaudhary; Humera Kausar; Fayez Althobaiti; Afshan Syed Abbas; Zawar Hussain; Naz Fatima; Erum Zafar; Wajiha Asif; Umair Afzal; Zoufishan Yousaf; Amjad Zafar; Steve M Harakeh; Samina Qamer
Journal:  Saudi J Biol Sci       Date:  2021-05-06       Impact factor: 4.219

Review 10.  Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis.

Authors:  Rimma Berenstein
Journal:  Biomark Insights       Date:  2015-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.